GlassScriptPhysician profile
Charles K Hill
NPI 1871600189
$15,266.80
in general payments reported to CMS, 2019-2025
53 companies · $2,403 in 2025
The $2,403 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,022 · 2020: $1,548 · 2021: $2,472 · 2022: $2,405 · 2023: $2,350 · 2024: $2,067 · 2025: $2,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,702 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,702.23 |
| Education | $117.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,681.86 | 2019-2025 | |
| Novo Nordisk INC | $1,545.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,489.75 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,315.97 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,144.41 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,003.92 | 2019-2025 | Jardiance, Ofev |
| Amgen INC. | $689.01 | 2019-2025 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $664.08 | 2019-2025 | Spravato |
| Novartis Pharmaceuticals Corporation | $606.81 | 2019-2025 | |
| Astellas Pharma US INC | $591.12 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $376.94 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Daiichi Sankyo INC. | $372.65 | 2020-2025 | Injectafer |
| Amarin Pharma, INC. | $361.70 | 2019-2021 | |
| Abbott Laboratories | $290.72 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $289.54 | 2021-2024 | Dexcom G6 Transmitter |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.